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Introduction
The World Wide Web has been identified as one of the “leading edge” data sources for
detecting patterns and changes in drug trends. Many Web 2.0 empowered social
platforms, including web forums and Twitter, provide venues for individuals to share their
experiences, post questions, and offer comments about different drugs, and thus can be
used as a very rich source of unfiltered and anonymous self-disclosures of drug use
behaviors. The study builds on interdisciplinary collaboration between the researchers at
the Center for Interventions, Treatment, and Addictions Research (CITAR), and the Ohio
Center of Excellence in Knowledge-enabled Computing (Kno.e.sis). In 2011, the two
centers initiated a study to develop automated data collection and analysis tools to
process web-based data on knowledge, attitudes, and behaviors related to the illicit use of
buprenorphine, OxyContin® and other pharmaceutical opioids. In the process of
developing entity identification techniques to automate coding and analysis of web-forum
data, the research team discovered extensive web-based discussions of extra-medical
use of loperamide (e.g., Imodium®), a piperidine derivative and an opioid agonist approved
by the U.S. Food and Drug Administration for the control of diarrhea symptoms. Because
of its general inability to cross the blood-brain barrier, loperamide is considered to have no
abuse potential and is available without a prescription. To date, little is known about the
extra-medical use of loperamide among illicit opioid users. This content analysis study
was designed to examine intentions of loperamide use as reflected in web-based
discussions as well as reported dosage and side effects.
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Results
The first post on loperamide use appeared in 2005, and in 2010-2011, there was a notable
increase in discussions related to loperamide (Figure 1). Almost 70% of posts discussed
loperamide as a remedy to self-treat opioid withdrawal symptoms. About 25% of the
sample discussed issues related to loperamide’s potential to cross blood-brain barrier to
produce euphoric or analgesic effects. The remaining posts included a few mentions of
its’ use as indicated (i.e., control diarrhea) or its’ purported efficacy to potentiate other
opioids (Table 1). Coder reliability assessment indicates excellent agreement in relation to
identifying intent of use (Table 2).
Content analysis indicates that withdrawal-related discussions of loperamide use
increased over time, while those related to its’ potential to cross blood-brain barrier and
produce a “high” or analgesia remained stable (Figure 2). Further, loperamide use to get
high was more commonly discussed in “theoretical” terms. The majority of such posts
expressed skeptical or ambivalent views regarding its’ potential to produce euphoria or
analgesia (Table 1). For example, the following views were expressed by the web-forum
participants:
Post A: “F… taking diarrhea medicine to get high! If it was possible to get
high off Imodium, it would be illegal like all the other good drugs. C’mon guys
just go buy some real drugs and stop wasting your time. It ain’t gonna work.”
Reply to post A: “Man, don’t be so negative. Are you going through wd
[withdrawals]? Just because it’s legal doesn’t mean there’s no potential… It
doesn’t hurt to try….”
“I’m a little behind on things. Are there any studies showing that loperamide
crosses the BBB [blood-brain barrier] in people or first-hand reports? If so, do
you have any links? This was going on for a while…. but if I remember correctly,
no one was successful. Thanks.”

Figure 1. Loperamide Mentions in Web-Based Discussions Over Time
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Data collection: A website that allows for the free discussion of illicit drugs and is
accessible for public viewing was selected for the study of loperamide use. The website
limits the number of active memberships at any given time period, but it has had over
2,500 unique members since its inception in 2004. The web-forum posts were retrieved
using Web Crawlers and retained in a local text corpus. All unique user names were
anonymized. The corpus was queried to extract posts with a mention of loperamide and
relevant brand/slang terms (“entity spotting”). Novel application of computer science
techniques allowed for automation and faster retrieval of relevant web posts. Over 1,290
posts, covering a time period between 2005 and 2011, were identified and entered into
NVivo data base for manual coding.
IRB procedures: Because postings on the selected website are made anonymously and
intended for public viewing, Wright State University’s IRB considered the study to be
exempt from the human subjects review.
Coding: A random sample of 258 (20%) posts was selected for content analysis. The
study used Complementary Explorative Data Analysis (CEDA) framework, which integrates
qualitative and quantitative methods in content analysis of media communications
(Sudweeks and Simoff, 1999). First, using a qualitative approach and preliminary “open”
coding of a subset of posts, a coding scheme was developed. Next, 258 posts were
coded to identify the intent of loperamide use, information on reported dosage and sideeffects. Qualitative and quantitative approaches were used to make sense of the coded
data and to discover temporal patterns of identified codes and themes.
Coder Reliability Assessment. A formal reliability sub-sample consisted of 129 (10%)
posts. First, codes related to the intent of loperamide use were reviewed, clarified and
pre-tested by the research team. The reliability sub-sample was then independently coded
by three coders (first and second authors and a research assistant). SPSS was used to
calculate: 1) percentage agreement; and 2) Cohen’s kappa, which takes into account
chance correction when calculating inter-coder agreement. Kappa of 0.40-0.75 indicates
acceptable and above 0.75 indicates excellent agreement (Neuendorf, 2009).
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Methods

Aims: Many websites provide a medium for individuals to share their experiences and
knowledge about different drugs. Such User-Generated Content (UGC) can be a rich data
source to study emerging drug use practices and trends. The study aims to examine webbased reports of loperamide use practices among illicit opioid users. Loperamide, a
piperidine derivative, is an opioid agonist approved for the control of diarrhea symptoms.
Because of its general inability to cross the blood-brain barrier, loperamide is considered
to have no abuse potential and is available without a prescription.
Methods: A website that allows for the free discussion of illicit drugs and is accessible for
public viewing was selected for analysis. Web-forum posts were retrieved using Web
Crawlers and retained in a local text corpus. All unique user names were anonymized. The
corpus was queried to extract posts with a mention of loperamide and relevant brand/
slang terms. Over 1200 posts were identified and entered into NVivo to assist with
consistent application of codes related to the reasons, dosage, and effects of loperamide
use.
Results: Since the first post in 2005, there has been a substantial rise in discussions
related to its use by non-medical opioid users, especially in 2010-2011. Loperamide was
primarily discussed as a remedy to alleviate a broad range of opiate withdrawal symptoms,
and was sometimes referred to as “poor man’s methadone.” Typical doses ranged from 70
mg to 200 mg per day, much higher than an indicated daily dose of 16 mg.
Conclusions: This study suggests that loperamide is being used extra-medically by
people who are involved with the abuse of opioids to control withdrawal symptoms. There
is a growing demand among people who are opioid dependent for drugs to control
withdrawal symptoms, and loperamide appears to fit that role. The study also highlights
the potential of the Web as a “leading edge” data source in identifying emerging drug use
practices.

Table 1. Content Analysis of Loperamide Mentions in Web-Based Posts (N=258)
Intentions and reported efficacy of loperamide use
N
%
Self-treatment of withdrawal symptoms
177
69.0%
Positive views
(79%)
Negative or ambivalent views
(21%)
Use to get high or control pain (potential to cross blood-brain barrier)
65
25.0%
Positive views
(31%)
Negative or ambivalent views
(69%)
Use to potentiate other opioids
7
2.7%
Use as indicated
6
2.3%
Other or undetermined
30
12.0%
Coder pair

Table 2. Coder Reliability Assessment
Use to self-treat withdrawal symptoms Potential to cross Blood Brain Barrier
Percent Agreement

A and B
A and C
C and B

87%
95%
91%

Cohen’s
Kappa
0.71
0.88
0.80

Percent Agreement
88%
96%
90%

Cohen’s
Kappa
0.63
0.86
0.68

Figure 2. Coding Results of Intent of Loperamide Use Over Time
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In contrast, most of withdrawal-related mentions of loperamide were classified as endorsing its’
efficacy to control a broad range of withdrawal symptoms (Table 1). The majority reported using
“megadoses” of loperamide, averaging 70 mg per day, and in some cases ranging from 100 mg to
200 mg per day. These doses are significantly higher than an indicated dose of 16 mg per day. For
example, web-forum participants shared the following opinions:
“If you take a shitload of loperamide, like 10-20 pills at once in withdrawal, you’ll get
relief from some of the physical symptoms. I’m not sure exactly how it works, but it’s
definitely MORE than just relieving the GI symptoms. I’m guessing if you just bombard
your blood with it, SOME of it has to make it through? Not sure.”
“Normally around 100 milligrams of loperamide will get me out of withdrawals.”
“Loperamide alone is enough to keep me well without being miserable, IF I
megadose.”
“This loperamide has saved my life during w/ds [withdrawals].... and made me even
more careless with my monthly meds.”
“But I just wanted to tell you that loperamide WILL WORK. I take 105 mg of
methadone/day, and recently have been running out early due to a renewed interest in
IVing that shit. 200mg of lope 100 pills will make me almost 100 [percent] again. It
brings the sickness down to the level of, say, a minor flu. Sleep returns, restlessness
dissipates. Sometimes a mild opiation is felt.”
“So you just stick with it. Don’t go and score big with your next paycheck.
Overcome the need to make everything numb. Learn to live with normality for a while.
It’ll all seem worthwhile soon enough. Go for a walk. Get out of the house. Go grab
some loperamide from the store, the desperate junky’s methadone.”
The most commonly discussed side effects of loperamide use were constipation, dehydration and
other types of gastrointestinal discomforts. Some also reported mild withdrawal symptoms from
using loperamide for an extended period of time.
“Loperamide is good for a day or two but the problem is on loperamide I lose all
desire to eat OR drink, or do anything, really.”
“I used to sing the praises of loperamide....and still do, as a short term standby until
you can score. Long term maintenance, it really wears you out. Starts to “feel” toxic
though I doubt it actually is toxic... After a few days I would get severely dehydrated
because it makes me lose all thirst … my stomach feels like I took a strong stimulant,
eating is basically impossible, constipation is surprisingly not bad but still there…”

Conclusions
The study contains several limitations, including issues surrounding representativeness of the
study results, lack of demographic and geographic information, and an inability to validate selfreported data. These limitations are mostly inherent to web-based studies and common in
research with hidden and hard-to-reach populations. Nevertheless, the preliminary results of this
web-based study identified new information about patterns of extra-medical drug use and selftreatment behaviors among illicit opioid users. Increasing web-based discussions about
loperamide use of to self-treat withdrawal symptoms are reflective of the rising rates of opioid
dependence disorders (McCabe et al., 2008; Substance Abuse and Mental Health Services
Administration (SAMHSA), July 15, 2010). They also indicate a growing demand among users
for accessible remedies to assist in their self-treatment efforts. The study highlights the
importance of the web-based data in informing drug use epidemiology and an urgent need to
incorporate leading-edge information processing techniques to facilitate automatic or semiautomatic knowledge discovery.
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